The control of blood pressure level as the prevention of cognitive impairment

The control of blood pressure level as the prevention of cognitive impairment

Today the prevalence of cognitive impairment is a large scale. At the end of the pathological process partial or complete, social, professional and common maladjustment and disability comes. One of the main factors of progression of cognitive impairment is a decrease in adherence to the therapy, for...

Full description

Bibliographic Details
Main Authors:	M V Melnik, I I Afonicheva, A A Kazyulin
Format:	Article
Language:	Russian
Published:	IP Morozov P.V. 2016-12-01
Series:	Системные гипертензии
Subjects:	arterial hypertension cognitive function lercanidipine
Online Access:	https://syst-hypertension.ru/2075-082X/article/viewFile/29161/pdf

Similar Items

The control of blood pressure level as the prevention of cognitive impairment
by: Melnik M.V., et al.
Published: (2016-12-01)

Organoprotection with arterial hypertension 2-3 degrees
by: I I Afonicheva, et al.
Published: (2018-12-01)

ASSESSMENT OF COGNITIVE FUNCTION IN PATIENTS WITH ESSENTIAL HYPERTENSION TREATED WITH LERCANIDIPINE
by: J. Tisaire-Sánchez, et al.
Published: (2011-04-01)

CALCIUM ANTAGONISTS IN ARTERIAL HYPERTENSION TREATMENT: SPECIFICS OF LERCANIDIPINE
by: I. O. Minushkina
Published: (2015-02-01)

A modern choice for patients with hypertension: the possibility of new calcium antagonist of III generation
by: E. I. Emelina, et al.
Published: (2015-11-01)

LERCANIDIPINE IN THE TREATMENT OF ARTERIAL HYPERTENSION
by: C. Beckey, et al.
Published: (2009-08-01)

LERCANIDIPINE, CALCIUM CHANNEL BLOCKER OF THE THIRD GENERATION: NEW POSSIBILITIES IN THE TREATMENT OF ARTERIAL HYPERTENSION
by: O. D. Ostroumova, et al.
Published: (2015-09-01)

Real and potential benefits of third-generation calcium antagonists
by: A A Kirichenko
Published: (2013-03-01)

THE EFFECTIVENESS OF LERCANIDIPINE IN REDUCING THE RISK OF ARTERIAL HYPERTENSION COMPLICATIONS
by: E. EL. Trisvetova
Published: (2015-09-01)

Combined pharmacotherapy for arterial hypertension: a view through the 2013 clinical practice guidelines
by: A V Rodionov
Published: (2013-06-01)

Clinical efficacy and cardioprotective capabilities of olmesartan and lercanidipine in the form of monotherapy and with their combined use in patients with arterial hypertension 1-2 degree
by: A. G Evdokimova, et al.
Published: (2017-03-01)

Consistence of the radial artery as a conduit used in aortocoronary bypass surgery, a possibility of preventing shunt spasm
by: T M Ripp, et al.
Published: (2012-12-01)

Calcium antagonist lercanidipine in hypertension
by: G. A Baryshnikova, et al.
Published: (2014-03-01)

CLINICAL EFFECTS AND RENOPROTECTIVE FACILITIES OF OLMESARTAN AND LERKANIDIPINEAS MONOTHERAPY AND WHEN COMBINED APPLICATION IN PATIENTS WITH ARTERIAL HYPERTENSION
by: A G Evdokimova, et al.
Published: (2016-03-01)

FIXED ANTIHYPERTENSIVE DRUGS COMBINATION SELECTION WITH THE AIM OF ORGANS PROTECTION
by: O. D. Ostroumova, et al.
Published: (2015-05-01)

POSITIONS OF CALCIUM CHANNEL BLOCKER LERCANIDIPINE ACCORDING TO EVIDENCE BASED CARDIOLOGY
by: Yu. V. Lukina, et al.
Published: (2016-01-01)

TREATMENT OF PATIENTS WITH ARTERIAL HYPERTENSION AND METABOLIC SYNDROME. THE ROLE OF THE COMBINATION DRUGS
by: A. M. Shilov, et al.
Published: (2015-09-01)

ANTIHYPERTENSIVE EFFICACY AND TOLERABILITY OFLERCANIDIPINE IN DAILY CLINICAL PRACTICE. THE ELYPSE STUDY
by: Vivencio Barrios, et al.
Published: (2010-08-01)

Pleiotropic features of dihydropyridine calcium channel antagonists
by: G S Anikin
Published: (2014-09-01)

HYPERTENSION IN POSTMENOPAUSAL WOMEN: RATIONALE FOR THE USE OF CALCIUM CHANNEL BLOCKERS IN ANTIHYPERTENSIVE THERAPY
by: O. A. Kislyak, et al.
Published: (2017-07-01)

DIHYDROPYRIDINE CALCIUM ANTAGONISTS AND THE TREATMENT OF ARTERIAL HYPERTENSION AND OBESITY PATIENTS IN ACCORDANCE WITH THE MODERN CLINICAL GUIDELINES
by: S. R. Gilyarevskyi, et al.
Published: (2014-04-01)

Cognitive impairment in patients with arterial hypertension: a relationship with the level and daily blood pressure profile and pathogenetic mechanisms
by: T. M. Ostroumova, et al.
Published: (2019-05-01)

RESISTANT HYPERTENSION IN A PATIENT WITH METABOLIC SYNDROME
by: O. M. Drapkina, et al.
Published: (2017-01-01)

Relationship between cardiac rhythm disorders, serum urotensin ІІ and angiotensin ІІ levels in patients with stage ii hypertension and carotid atherosclerosis in dynamics of treatment with candesartan and lercanidipine
by: O. V. Demidenko,, et al.
Published: (2016-10-01)

Assessment of associations of cognitive complaints with increased blood pressure levels in young and middle-aged women in Novosibirsk population
by: A. V. Sukhanov, et al.
Published: (2020-12-01)

The Protective Effect of Lercanidipine on Indomethacin-Induced Gastric Ulcers in Rats
by: Durdu Altuner, et al.
Published: (2020-08-01)

FIXED COMBINATION OF THE CALCIUM CHANNEL BLOCKER LERCANIDIPINE AND ANGIOTENSIN CONVERTING ENZYME INHIBITOR ENALAPRIL: POSSIBILITY OF USAGE
by: O. D. Ostroumova, et al.
Published: (2015-09-01)

COGNITIVE IMPAIRMENTS IN PATIENTS WITH ARTERIAL HYPERTENSION
by: N.KH. KHAMIDOV, et al.
Published: (2019-06-01)

Arterial hypertension and cognitive impairment: multimodal approach for patient care and nicergoline use
by: O. D. Ostroumova, et al.
Published: (2020-07-01)

Lercanidipine as a calcium antagonist of the third generation: a review of effectiveness in the hypertension treatment
by: V S Zadionchenko, et al.
Published: (2013-12-01)

Lercanidipine’s Antioxidative Effect Prevents Noise-Induced Hearing Loss
by: Zhaoqi Guo, et al.
Published: (2024-03-01)

Application of lercanidipine in the treatment of hypertension
by: G. G Shehyan, et al.
Published: (2014-06-01)

MILDRONATE POTENTIAL FOR CORRECTING COGNITIVE DYSFUNCTION IN ELDERLY PATIENTS WITH ARTERIAL HYPERTENSION
by: M. E. Statsenko, et al.
Published: (2011-08-01)

Values of ambulatory blood pressure monitoring for prediction of cognitive function impairment in elderly hypertensive patients
by: Khaled S. Mahmoud, et al.
Published: (2015-03-01)

The Effects of Eprosartan Mesylate and Lercanidipine on Reducing Microalbuminuria in Patients with Nephropathy due to Type 2 Diabetes
by: Botir T. Daminov, PhD, ScD, et al.
Published: (2013-06-01)

Optimizing therapy for cardiovascular diseases: proven organ-protective and preventive effects of pitavastatin and lercanidipine: A review
by: Marina G. Bubnova
Published: (2022-07-01)

TREATMENT OF COGNITIVE IMPAIRMENT AFTER STROKE
by: V. V. Zakharov, et al.
Published: (2018-02-01)

Arterial hypertension treatment with a calcium channel blocker and an ACE inhibitor. Benefits of combination therapy
by: E. O. Taratukhin
Published: (2013-06-01)

The association between high blood pressure and cognitive impairment in elderly: a brief report
by: Mahmudi Mohammad Jafar, et al.
Published: (2012-03-01)

Pulse pressure and cognitive impairment
by: O. D. Ostroumova, et al.
Published: (2021-02-01)